Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary CD4+ T cells orchestrate immune responses and destruction of allogeneic organ transplants, but how this process is regulated on a transcriptional level remains unclear. Here, we demonstrated that interferon regulatory factor 4 (IRF4) was a key transcriptional determinant controlling T cell responses during transplantation. IRF4 deletion in mice resulted in progressive establishment of CD4+ T cell dysfunction and long‐term allograft survival. Mechanistically, IRF4 repressed PD‐1, Helios, and other molecules associated with T cell dysfunction. In the absence of IRF4, chromatin accessibility and binding of Helios at PD‐1 cis‐regulatory elements were increased, resulting in enhanced PD‐1 expression and CD4+ T cell dysfunction. The dysfunctional state of Irf4‐deficient T cells was initially reversible by PD‐1 ligand blockade, but it progressively developed into an irreversible state. Hence, IRF4 controls a core regulatory circuit of CD4+ T cell dysfunction, and targeting IRF4 represents a potential therapeutic strategy for achieving transplant acceptance. Graphical Abstract Figure. No caption available. HighlightsAblation of IRF4 induces transplant acceptance by establishing T cell dysfunctionIRF4 represses PD‐1, Helios, and other molecules associated with T cell dysfunctionIrf4-/- T cell dysfunction is initially reversible but later becomes irreversibleTrametinib inhibits IRF4, abrogates EAE development, and prolongs allograft survival &NA; CD4+ T cells drive allogeneic organ transplant destruction, but how this is regulated transcriptionally remains unclear. Wu et al. report that IRF4 deletion in T cells leads to the establishment of T cell dysfunction and long‐term allograft survival. Therefore, targeting IRF4 represents a therapeutic opportunity for achieving transplant acceptance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 8×
“Hence, IRF4 deletion in activated CD4+ T cells led to increased expression of PD-1, Helios, PLAGL1, CD160, CD73, and FR4, which are characteristic markers of dysfunctional T cells (Crawford et al., 2014; Fathman and Lineberry, 2007; Martinez et al., 2012; Wherry and Kurachi, 2015).”
InfluentialNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses
Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J. M., Chu, T.-T., Corcoran, L., Treuting, P., Klein, U., & Rudensky, A. Y. (2009) · Nature · doi:10.1038/nature07674 · Cited by 958
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · cited 1×
“…infections and cancers sustainably express various inhibitory receptors, including programmedcell deathprotein1 (PD-1),CD160, lymphocyte-activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), and cytotoxic T lymphocyte antigen 4 (CTLA-4) (Crawford et al., 2014; Schietinger et al., 2016).”
Cretney, E., Xin, A., Shi, W., Minnich, M., Masson, F., Miasari, M., Belz, G. T., Smyth, G. K., Busslinger, M., Nutt, S. L., et al. (2011) · Nature Immunology · doi:10.1038/ni.2006 · Cited by 605
Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function
Mittrücker, H.-W., Matsuyama, T., Grossman, A., Kündig, T. M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P. S., & Mak, T. W. (1997) · Science · doi:10.1126/science.275.5299.540 · Cited by 583 · cited 2×
“Irf4 / mice has been previously described (Mittr€ucker et al., 1997; e3 Immunity 47, 1–15.e1–e6, December 19, 2017 Ochiai et al., 2013).”
Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells
Staudt, V., Bothur, E., Klein, M., Lingnau, K., Reuter, S., Grebe, N., Gerlitzki, B., Hoffmann, M., Ulges, A., Taube, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.014 · Cited by 554 · cited 4×
“IRF4 controls the differentiation of Th2, Th9, Th17, Tfh, Treg, and cytotoxic effector CD8 T cells (Bollig et al., 2012; Br€ ustle et al., 2007; Cretney et al., 2011; Huber et al., 2008; Staudt et al., 2010; Yao et al., 2013; Zheng et al., 2009).”
InfluentialReversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
Kim, H.-J., Barnitz, R. A., Kreslavsky, T., Brown, F. D., Moffett, H., Lemieux, M. E., Kaygusuz, Y., Meissner, T., Holderried, T. A. W., Chan, S., et al. (2015) · Science · doi:10.1126/science.aad0616 · Cited by 441 · cited 1×
“Helios has been shown to be highly expressed by natural Treg cells, exhausted T cells, and tolerated T cells (Crawford et al., 2014; Kim et al., 2015; Ross et al., 2014; Singer et al., 2016).”
Cited by
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 459
Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., & Yang, W. (2020) · Small · doi:10.1002/smll.202001704 · Cited by 426
Trapecar, M., Communal, C., Velazquez, J., Maass, C. A., Huang, Y.-J., Schneider, K., Wright, C. W., Butty, V., Eng, G., Yilmaz, O., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.02.008 · Cited by 218
CoBATCH for High-Throughput Single-Cell Epigenomic Profiling
Wang, Q., Xiong, H., Ai, S., Yu, X., Liu, Y., Zhang, J., & He, A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.015 · Cited by 213
Metadata
- Authors
- Wu, J., Zhang, H., Shi, X., Xiao, X., Fan, Y., Minze, L. J., Wang, J., Ghobrial, R. M., Xia, J., Sciammas, R., Li, X. C., & Chen, W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 47
- Issue
- 6
- Pages
- 1114-1128.e6
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2773141414
- Cited by
- 92
- References
- 9
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.